Cibus (CBUS) Income from Non-Controlling Interests (2023 - 2025)
Cibus (CBUS) posted Income from Non-Controlling Interests of -$662000.0 for Q4 2025, up 13.12% sequentially from -$762000.0 in Q3 2025, and up 75.5% YoY from -$377208.8 in Q4 2024.
Cibus (CBUS) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Cibus has reported Income from Non-Controlling Interests for 3 years, with the latest figure at -$662000.0 in Q4 2025.
- Quarterly Income from Non-Controlling Interests rose 75.5% year-over-year to -$662000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.1 million (up 83.67% YoY) and the FY2025 annual result came in at -$5.1 million, up 83.67% from the prior year.
- Income from Non-Controlling Interests advanced to -$662000.0 in Q4 2025 per CBUS's latest filing, from -$762000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$662000.0 in Q4 2025 and troughed at -$60.1 million in Q4 2023.
- A 3-year average of -$9.7 million and a median of -$2.7 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests plunged 165.35% in 2024, then soared 96.45% in 2025.
- Over 3 years, Income from Non-Controlling Interests stood at -$60.1 million in 2023, then jumped by 95.5% to -$2.7 million in 2024, then surged by 75.5% to -$662000.0 in 2025.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$662000.0, -$762000.0, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -662,000.00 |
| Sep 30, 2025 | -762,000.00 |
| Jun 30, 2025 | -1.19 Mn |
| Mar 31, 2025 | -2.51 Mn |
| Dec 31, 2024 | -2.70 Mn |
| Sep 30, 2024 | -21.49 Mn |
| Jun 30, 2024 | -3.60 Mn |
| Mar 31, 2024 | -3.54 Mn |
| Dec 31, 2023 | -60.09 Mn |
| Sep 30, 2023 | -8.10 Mn |
| Jun 30, 2023 | -1.82 Mn |